Longboard Pharmaceuticals, Inc.

NASDAQ:LBPH

29.31 (USD) • At close September 18, 2024
Bedrijfsnaam Longboard Pharmaceuticals, Inc.
Symbool LBPH
Munteenheid USD
Prijs 29.31
Beurswaarde 1,140,144,902
Dividendpercentage 0%
52-weken bereik 3.6 - 40.48
Industrie Biotechnology
Sector Healthcare
CEO Mr. Kevin R. Lind
Website https://www.longboardpharma.com

An error occurred while fetching data.

Over Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which

Vergelijkbare Aandelen

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

EFTR

0.04 USD

LENSAR, Inc. logo

LENSAR, Inc.

LNSR

4.2 USD

Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc.

PYXS

3.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)